source
- Caribou Biosciences halts CAR-T programs and cuts staff amid funding shortfallCaribou Biosciences, a CRISPR gene-editing company co-founded by Nobel laureate Jennifer Doudna, announced it will stop work on its off-the-shelf CAR-T cancer therapies. The decision follows the c…
- Cerevance reports positive Phase 3 results for Parkinson’s drug solengeprasCerevance, a Boston biotech spinout from Takeda, announced that its experimental Parkinson’s drug solengepras achieved its primary endpoint in a Phase 3 trial. The trial enrolled 341 patients with…